21
Participants
Start Date
August 31, 2012
Primary Completion Date
September 30, 2016
Study Completion Date
September 30, 2016
Sirolimus, Cyclophosphamide, Topotecan
Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
UCSF Benioff Children's Hospital, San Francisco
Hyundai Hope On Wheels
OTHER
University of California, San Francisco
OTHER